Literature DB >> 19038573

The dual role of IL-6-type cytokines on bone remodeling and bone tumors.

Frédéric Blanchard1, Laurence Duplomb, Marc Baud'huin, Bénédicte Brounais.   

Abstract

Many factors such as vitamins, hormones and cytokines, control bone metabolism and remodeling. Cytokines of the interleukin-6 family, by acting on bone cells (i.e. osteoblasts and osteoclasts), have an important role in the bone tissue but they recently appeared as double-edged swords. They sustain bone formation but they can also drive bone loss in various osteolytic pathologies. Similarly, development of bone cancers can be either prevented or enhanced by these cytokines, depending on the cell type, the stage of the tumor and the bone environment. This dual effect is also apparent at the level of the signal transducer and activator of transcription and the mitogen-activated protein kinases, the two main signaling pathways that mediate opposite effects in bone cells.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19038573     DOI: 10.1016/j.cytogfr.2008.11.004

Source DB:  PubMed          Journal:  Cytokine Growth Factor Rev        ISSN: 1359-6101            Impact factor:   7.638


  69 in total

1.  Crystal structure of the entire ectodomain of gp130: insights into the molecular assembly of the tall cytokine receptor complexes.

Authors:  Yibin Xu; Nadia J Kershaw; Cindy S Luo; Priscilla Soo; Michael J Pocock; Peter E Czabotar; Douglas J Hilton; Nicos A Nicola; Thomas P J Garrett; Jian-Guo Zhang
Journal:  J Biol Chem       Date:  2010-05-20       Impact factor: 5.157

Review 2.  Interleukin-6 in bone metastasis and cancer progression.

Authors:  Tasnim Ara; Yves A Declerck
Journal:  Eur J Cancer       Date:  2010-03-23       Impact factor: 9.162

Review 3.  Infection, inflammation, and bone regeneration: a paradoxical relationship.

Authors:  M V Thomas; D A Puleo
Journal:  J Dent Res       Date:  2011-01-19       Impact factor: 6.116

4.  Cell encapsulating biomaterial regulates mesenchymal stromal/stem cell differentiation and macrophage immunophenotype.

Authors:  David Antonio Cantu; Peiman Hematti; Weiyuan John Kao
Journal:  Stem Cells Transl Med       Date:  2012-10-10       Impact factor: 6.940

5.  Immune and inflammatory pathways are involved in inherent bone marrow ossification.

Authors:  Umut Atakan Gurkan; Ryan Golden; Vipuil Kishore; Catherine P Riley; Jiri Adamec; Ozan Akkus
Journal:  Clin Orthop Relat Res       Date:  2012-09       Impact factor: 4.176

6.  Different signaling mechanisms regulating IL-6 expression by LPS between gingival fibroblasts and mononuclear cells: seeking the common target.

Authors:  Junfei Jin; Kamala P Sundararaj; Devadoss J Samuvel; Xiaoming Zhang; Yanchun Li; Zhongyang Lu; Maria F Lopes-Virella; Yan Huang
Journal:  Clin Immunol       Date:  2012-02-10       Impact factor: 3.969

7.  STAT3-mediated SMAD3 activation underlies Oncostatin M-induced Senescence.

Authors:  Benjamin L Bryson; Damian J Junk; Rocky Cipriano; Mark W Jackson
Journal:  Cell Cycle       Date:  2016-11-28       Impact factor: 4.534

8.  Inhibition of prostate cancer osteoblastic progression with VEGF121/rGel, a single agent targeting osteoblasts, osteoclasts, and tumor neovasculature.

Authors:  Khalid A Mohamedali; Zhi Gang Li; Michael W Starbuck; Xinhai Wan; Jun Yang; Sehoon Kim; Wendy Zhang; Michael G Rosenblum; Nora M Navone
Journal:  Clin Cancer Res       Date:  2011-02-22       Impact factor: 12.531

Review 9.  The Osteocyte: New Insights.

Authors:  Alexander G Robling; Lynda F Bonewald
Journal:  Annu Rev Physiol       Date:  2020-02-10       Impact factor: 19.318

Review 10.  Understanding and targeting osteoclastic activity in prostate cancer bone metastases.

Authors:  J L Sottnik; E T Keller
Journal:  Curr Mol Med       Date:  2013-05       Impact factor: 2.222

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.